Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Renishaw hikes FY guidance, introduces tariff surcharge

(Sharecast News) - Engineering firm Renishaw hiked FY guidance on Thursday as it introduced a tariff surchage to help offset the impacts of Donald Trump's so-called "reciprocal" tariffs. Renishaw posted Q3 revenues of £180.7m, up 5% year-on-year, accelerating from H1's 3% growth rate, while adjusted pre-tax profits were up approximately 27.65% quarter-on-quarter at £30.0m. Year-to-date, adjusted pre-tax profits were £87.5m, up 1%, while statutory pre-tax profits were down 1% at £85.6m.

The FTSE 250-listed group said exports to the US, which make up approximately 20% of total revenues, will be hit with either 20% tariffs on aluminium and steel or the 10% "reciprocal" tariffs on output from its factories in the UK, Ireland and India.

However, Renishaw raised its FY revenue guidance to £700.0m-720.0m, up from £695.0m-735.0m, while adjusted pre-tax profit guidance was upped to £109.0m-127.0m from £105.0m-135.0m.

"We have continued to deliver steady growth in mixed market conditions, with improving demand from semiconductor equipment builders throughout the year and a recent rise in machine tool probing sales. To support our growth strategy, we continue to focus on productivity, managing our portfolio of businesses and making targeted investments in our people, our production facilities, and our new product pipeline," said Renishaw.

"We enter the final quarter of the year with good momentum, but we are mindful of the volatile economic backdrop and its potential to impact our customers' investment decisions. We are therefore continuing to focus on pricing strategy and cost control."

As of 1050 BST, Renishaw shares had surged 15.7% to 2,643.84p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.